Atlas Trials

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

Clinical trial NCT06092879 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06092879
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Chronic Myeloid Leukemia
Start date
2024-03-06
Primary completion
2026-12-15
Enrollment
201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.